• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西班牙巴斯克地区婴儿因呼吸道合胞病毒感染住院的风险因素

Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

作者信息

Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, Pérez-Yarza E, Pérez-Trallero E

机构信息

Servicio de Microbiología, Hospital Donostia, and Deparamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad del País Vasco, San Sebastián, Spain.

出版信息

Epidemiol Infect. 2006 Jun;134(3):506-13. doi: 10.1017/S0950268805005571.

DOI:10.1017/S0950268805005571
PMID:16638164
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2870431/
Abstract

This study analysed the role of several risk factors for hospitalization due to community-acquired, respiratory syncytial virus (RSV) infection. The risk factors detected in infants hospitalized for RSV infection in the first 24 months of life were compared with those in the general infant population in our region. There were 361 episodes of hospitalization in 357 infants. Eighty per cent of the infants did not present underlying conditions for severe RSV infection and only 10 (3%) were candidates for palivizumab prophylaxis. In multivariate analysis, birthweight of <2500 g was independently associated with hospitalization for RSV infection and was the most commonly detected medical risk factor. Other risk factors were maternal age at delivery <25 years, birth in the second half of the year, prematurity, suburban residence and congenital heart disease. In conclusion, together with well-known risk factors, we found that low birthweight was an independent factor for severe RSV infection.

摘要

本研究分析了几种社区获得性呼吸道合胞病毒(RSV)感染所致住院风险因素的作用。将24个月内因RSV感染住院的婴儿中检测到的风险因素与本地区普通婴儿群体中的风险因素进行比较。357名婴儿中有361次住院发作。80%的婴儿不存在严重RSV感染的基础疾病,仅有10名(3%)符合帕利珠单抗预防用药条件。多因素分析显示,出生体重<2500 g与RSV感染住院独立相关,是最常检测到的医学风险因素。其他风险因素包括分娩时母亲年龄<25岁、下半年出生、早产、居住在郊区以及先天性心脏病。总之,除了众所周知的风险因素外,我们发现低出生体重是严重RSV感染的独立因素。

相似文献

1
Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.西班牙巴斯克地区婴儿因呼吸道合胞病毒感染住院的风险因素
Epidemiol Infect. 2006 Jun;134(3):506-13. doi: 10.1017/S0950268805005571.
2
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.帕利珠单抗预防对降低早产儿呼吸道合胞病毒住院率的影响。
Pediatr Infect Dis J. 2003 Sep;22(9):823-7. doi: 10.1097/01.inf.0000086403.50417.7c.
3
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.帕利珠单抗是一种人源化呼吸道合胞病毒单克隆抗体,可降低高危婴儿因呼吸道合胞病毒感染而住院的几率。IMpact-RSV研究小组。
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.
4
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.1998年至2002年帕利珠单抗预防呼吸道合胞病毒疾病:四年使用帕利珠单抗的结果
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84.
5
Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.帕利珠单抗预防对阿拉斯加高危原住民婴儿呼吸道合胞病毒住院率的影响。
Pediatr Infect Dis J. 2003 Jun;22(6):540-5. doi: 10.1097/01.inf.0000069768.34383.18.
6
Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.帕利珠单抗:作为预防严重呼吸道合胞病毒感染药物的应用综述
Paediatr Drugs. 2004;6(3):177-97. doi: 10.2165/00148581-200406030-00004.
7
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.呼吸道合胞病毒预防在早产儿中的成本效益
Pediatrics. 1999 Sep;104(3 Pt 1):419-27. doi: 10.1542/peds.104.3.419.
8
Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.在首个呼吸道合胞病毒(RSV)季节接受帕利珠单抗预防治疗的早产儿,其第二个RSV季节的呼吸道疾病及住院率。
J Chemother. 2009 Jun;21(3):302-10. doi: 10.1179/joc.2009.21.3.302.
9
The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.加拿大儿科感染研究协作网络对妊娠33至35足周出生的婴儿呼吸道合胞病毒感染住院预测因素的研究。
Pediatr Infect Dis J. 2004 Sep;23(9):806-14. doi: 10.1097/01.inf.0000137568.71589.bd.
10
Prevention of respiratory syncytial virus infection with palivizumab.使用帕利珠单抗预防呼吸道合胞病毒感染。
Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8.

引用本文的文献

1
Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.2010 - 2022年西班牙巴利亚多利德住院婴儿呼吸道合胞病毒风险概况及与流感和新冠病毒对照情况比较
Infect Dis Ther. 2024 Nov;13(11):2395-2413. doi: 10.1007/s40121-024-01058-2. Epub 2024 Oct 12.
2
Inpatient burden of respiratory syncytial virus (RSV) in Switzerland, 2003 to 2021: an analysis of administrative data.瑞士 2003 年至 2021 年呼吸道合胞病毒(RSV)住院患者负担:基于行政数据的分析。
Euro Surveill. 2024 Sep;29(39). doi: 10.2807/1560-7917.ES.2024.29.39.2400119.
3
Respiratory Syncytial Virus Outbreak in Infants and Young Children during COVID-19 Pandemic in Taiwan.台湾地区新冠疫情期间婴幼儿呼吸道合胞病毒暴发
Children (Basel). 2023 Mar 28;10(4):629. doi: 10.3390/children10040629.
4
Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.预防性治疗可保护先天性心脏病婴儿免受 RSV 严重感染:意大利观察性回顾性研究:先天性心脏病患儿使用帕利珠单抗预防
Ital J Pediatr. 2023 Jan 11;49(1):4. doi: 10.1186/s13052-022-01399-z.
5
Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia.干扰素对呼吸道合胞病毒肺炎新生儿的疗效及安全性
Exp Ther Med. 2020 Dec;20(6):220. doi: 10.3892/etm.2020.9350. Epub 2020 Oct 15.
6
Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.魁北克省 33-35 孕周出生婴儿撤除非呼吸合胞病毒免疫预防的成本分析:一项多中心回顾性研究。
Pediatr Infect Dis J. 2020 Aug;39(8):694-699. doi: 10.1097/INF.0000000000002719.
7
The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.儿童、家庭和卫生服务因素对生命前 3 年呼吸道合胞病毒(RSV)住院的影响:2009 至 2015 年苏格兰出生队列研究
Euro Surveill. 2019 Jan;24(1). doi: 10.2807/1560-7917.ES.2019.24.1.1800046.
8
New therapies for acute RSV infections: where are we?急性 RSV 感染的新疗法:我们在哪里?
Eur J Pediatr. 2019 Feb;178(2):131-138. doi: 10.1007/s00431-018-03310-7. Epub 2019 Jan 4.
9
Respiratory syncytial virus hospitalization in children in northern Spain.西班牙北部儿童呼吸道合胞病毒住院情况。
PLoS One. 2018 Nov 15;13(11):e0206474. doi: 10.1371/journal.pone.0206474. eCollection 2018.
10
Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors.立陶宛、拉脱维亚和爱沙尼亚晚期早产儿因下呼吸道感染住院情况:发病率、疾病严重程度及危险因素。
Acta Med Litu. 2018;25(2):76-85. doi: 10.6001/actamedica.v25i2.3760.

本文引用的文献

1
Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.西班牙对孕33至35周出生的早产儿因呼吸道合胞病毒感染需住院治疗的相关危险因素进行的病例对照研究。
Pediatr Infect Dis J. 2004 Sep;23(9):815-20. doi: 10.1097/01.inf.0000136869.21397.6b.
2
The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.加拿大儿科感染研究协作网络对妊娠33至35足周出生的婴儿呼吸道合胞病毒感染住院预测因素的研究。
Pediatr Infect Dis J. 2004 Sep;23(9):806-14. doi: 10.1097/01.inf.0000137568.71589.bd.
3
Lower respiratory tract illness and RSV prophylaxis in very premature infants.极早产儿的下呼吸道疾病与呼吸道合胞病毒预防
Arch Dis Child. 2004 Jun;89(6):562-7. doi: 10.1136/adc.2003.028282.
4
[Exposure to smoking during pregnancy: Barcelona (Spain) 1994-2001].
An Pediatr (Barc). 2004 Feb;60(2):139-41. doi: 10.1016/s1695-4033(04)78234-x.
5
Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study.呼吸道合胞病毒感染——住院的危险因素:一项病例对照研究。
Acta Paediatr. 2003 Nov;92(11):1314-21.
6
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.帕利珠单抗和呼吸道合胞病毒免疫球蛋白静脉注射剂预防呼吸道合胞病毒感染的修订使用指征。
Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.
7
Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia.因细支气管炎或呼吸道合胞病毒肺炎住院的婴儿的并发症。
J Pediatr. 2003 Nov;143(5 Suppl):S142-9. doi: 10.1067/s0022-3476(03)00514-6.
8
Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.1997年至2000年美国婴儿中重症呼吸道合胞病毒(RSV)的近期趋势。
J Pediatr. 2003 Nov;143(5 Suppl):S127-32. doi: 10.1067/s0022-3476(03)00510-9.
9
Hospitalization for respiratory syncytial virus in the paediatric population in Spain.西班牙儿童人群呼吸道合胞病毒感染的住院情况。
Epidemiol Infect. 2003 Oct;131(2):867-72. doi: 10.1017/s0950268803008926.
10
Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.因呼吸道合胞病毒细支气管炎入住重症监护病房:帕利珠单抗使用前的全国性调查。
Pediatrics. 2003 Sep;112(3 Pt 1):548-52. doi: 10.1542/peds.112.3.548.